Abstract. RSK4 has been shown to inhibit the growth of certain cancer cells. The aim of this study was to construct a lentiviral vector of RSK4-shRNA (Lenti-RSK4-shRNA) to specifically block the expression of RSK4 in the human breast adenocarcinoma cell line MCF-7, and investigate the effect of the RSK4 gene on cell proliferation and invasion in vitro and in vivo. Lenti-RSK4-shRNA was stably transfected into MCF-7 cells. RSK4 mRNA and protein expression were measured by fluorescence quantitative RT-PCR and western blot analysis. Cell proliferation was evaluated by MTT assays and flow cytometric analysis. Invasion was evaluated by Transwell assays and xenograft nude mouse models. The expression of RSK4 mRNA, Ki-67 mRNA, cyclin D1 mRNA, CXCR4 mRNA and E-cadherin mRNA of tumor xenografts were detected by fluorescence quantitative RT-PCR. Significant decreases in RSK4 mRNA and protein expression was detected in MCF-7 cells carrying lentiviral RSK4-shRNA vector. The cell proliferation was significantly promoted in the RSK4-shRNA group as compared to that in the negative and blank control group. The number of cells in the S phase in the RSK4-shRNA group was significantly greater than the blank and negative control groups (P<0.05). Furthermore, the number of invading cells was increased in the RSK4-shRNA group (P<0.05). In vivo, we also found that the knockdown of RSK4 promoted tumorigenicity and migration in the xenograft nude mouse model. In addition, we showed that the RSK4 mRNA and E-cadherin mRNA expression were significantly lower in the RSK4-shRNA group compared to that in negative and blank control group (both P<0.05). Moreover, the number of Ki-67 mRNA, cyclin D1 mRNA and CXCR4 mRNA were higher in the RSK4-shRNA group compared to that in negative and blank control group (both P<0.05). In conclusion, downregulation of RSK4 expression is indicated to be associated with tumor cell proliferation and invasion, and silencing of the RSK4 may be involved in the development and progression of breast cancer through the changes of Ki-67, cyclin D1, CXCR4 and E-cadherin, and suggesting that RSK4 may act as a potential cancer suppressor gene and therapeutic target for the treatment of breast cancer.

Introduction

Breast cancer is one of the most common cancers and the leading cause of cancer death in females, accounting for 23% of the total cancer cases and 14% of the cancer deaths, and the incidence is still increasing (1). The major dilemma is that many women suffering from breast cancer end up with metastatic breast cancer (MBC) and recurrence, even though they all received surgery, adjuvant chemotherapy or and radiotherapy (2). At present, with better understanding of breast cancer progression with molecular markers such as Her-2, VEGF and EGFR, the treatment of breast cancer has entered a new era of molecular targeted therapy, from which more and more patients could benefit (3). Due to heterogeneity of breast tumor, the current treatments are invalid. Exploring new gene-related breast cancer and further clarifying the mechanism of these genes is essential to overcome breast adenocarcinoma metastasis and recurrence.

RSK is a serine-threonine kinase and belongs to the p90 ribosomal S6 kinase family (the 90,000 ribosomal S6 kinase RPS6KA), which is an important downstream effector of Ras-MAPKs signaling cascade (4-6). RSK consists of four isoforms of RSK1, RSK2, RSK3, and RSK4 (7), RSKs play a crucial role in the stimulation of cellular proliferation and survival via phosphorylation and regulation of the transcription factors, kinases, cyclin-dependent kinase inhibitor, p27Kip1, the tumor suppressor, tuberin, and the pro-apoptotic protein, Bad (8-10). An important role for RSKs is suggested in the regulation of the actin cytoskeleton for cellular migration (11). RSK4 is an outlier and functionally distinct, showing low expression compared with other RSKs, and overexpression of RSK4 may restrict cell growth (12). Several studies have reported that high expression of RSK4 in breast cancer cells is anti-oncogenic, anti-invasive, and anti-metastatic (13), and RSK4 also exhibits a tumor suppressor effect in colon and renal carcinomas (14).

RNA interference (RNAi) is a post-transcriptional process by which double-stranded RNA triggers the degradation
The double-stranded RNA is processed into short, 21- to 22-nucleotide double-stranded RNAs in the cell (15). The use of the RNAi is a powerful tool to block target gene expression has greatly facilitated the understanding of gene function (16).

In the present study, we used Lentiv-RSK4-siRNA vectors interfering with expression of RSK4 gene in MCF-7 cells, and investigated its effects on cell proliferation and invasion. In addition, we explored the changes of Ki-67, cyclin D1, CXCR4, and E-cadherin in xenograft tumors.

Materials and methods

Construction and transfection of shRNAs for RSK4. shRNA targeting human RSK4 gene and a non-targeting RNA were synthesized by GeneChem Technology Co., Ltd. (Shanghai, China). The RNAi sequences that target RSK4 were GATTATCGACC-3' and reverse, 5'-GGATCTCGGCCA-3' (200 bp). The reaction conditions for the real-time PCR was 95˚C for 30 sec followed by 40 cycles of 95˚C for 5 sec and 60˚C for 30 sec. All reactions were performed in Taq™ II (Tli RNaseH Plus) according to the manufacturer's instructions. Primers for RSK4, Ki-67, cyclin D1, E-cadherin, CXCR4 and GAPDH were as follows: RSK4 forward, 5'-ATATGGACCCACATCGGG-3' and reverse, 5'-AGCAGCTACTAGCTTTAGAA-3' (191 bp); Ki-67 forward, 5'-AGAGAGAGTCTCTACATCCGCA-3' and reverse, 5'-CATGTGACCTTTTGAGACCAT-3' (157 bp); cyclin D1 forward, 5'-AGGAACAGAAGTTGGAGGAGG-3' and reverse, 5'-GATGGAGGATGTCGGTGATATG-3' (192 bp); E-cadherin forward, 5'-GGTCTTCTTCGGACACCCT-3' and reverse, 5'-GAGAAGTCTCTCCGCTCAGC-3' (136 bp); CXCR4 forward, 5'-ACCACAGTCATCCCTCATTCT-3' and reverse, 5'-TCTCAAACTCACACCCCTGTC-3' (128 bp); and GAPDH forward, 5'-AAGAAGGGTGGTGAAACCGGC-3' and reverse, 5'-ACCACCTGGTTGCTGAGCC-3' (200 bp). The reaction conditions for the real-time PCR was 95˚C for 30 sec followed by 40 cycles of 95˚C for 5 sec and 60˚C for 30 sec. All reactions were performed in triplicate. Results were analyzed by calculating the ΔCt values for target gene and GAPDH using the following formula: 

$$-\Delta \Delta Ct = \Delta Ct \text{ of control group } - \Delta Ct \text{ of the treated group}$$

and the relative expression of target gene in each group was calculated using the 2^-\Delta \Delta Ct method.

RNA extraction and qRT-PCR. Total RNA extraction from different groups used TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer's protocol. The RNA concentration was measured by ultraviolet (UV) light at 260 nm, and the integrity of the extracted total RNA was detected by 1% agarose gel electrophoresis. Quantitative real-time PCR expression was observed by fluorescence microscopy (Olympus, Tokyo, Japan) 48 h after transfection, and cells were collected at 72 h after transfection for in vivo experiments.

MTT assay. The cells transfected with lentivirus RSK4-shRNA, lentivirus negative-shRNA and MCF-7 were harvested, and cell suspension concentration was adjusted to a density of 1x10^5 cells/ml, plated into a 96-well plate (2x10^3 cells/well). Cell proliferation was assessed at 1, 2, 3, 4, and 5 days following the instructions of the MTT proliferation assay kit (Sigma, USA). The experiment was performed three times.

Cell cycle assay. The cells transfected with lentivirus RSK4-shRNA, lentivirus negative-shRNA and MCF-7 were collected, and cell suspension concentration was adjusted to a density of 1x10^5 cells/ml. The cells were washed with PBS and fixed in 4% paraformaldehyde for 30 min. Invasive cells were stained with crystal violet for 30 min and washed in PBS for 10 min. Invasive cells were counted from five random microscopic fields of each membrane, and the average of cells was calculated. All the experiments in each group were performed in triplicate.

In vivo study of breast adenocarcinoma xenograft tumor model in nude mice. Animal experiments were approved by the Animal Center Animal Care and Use Committee of Guangxi Medical University. Five-week-old female BALB/c nude mice (weight, 16-20 g) were purchased from Guangxi Medical University Experimental Animal Center.
were fed and housed in laminar flow cabinets, pathogen-free animal facility, at a constant temperature (25-28˚C) and humidity. Mice were randomly divided into three groups with 13 mice/group: lentivirus RSK4-shRNA (RSK4-shRNA), lentivirus negative-shRNA (negative) and MCF-7 control (blank) group. The RSK4-shRNA group of nude mice were subcutaneously injected with MCF-7 cells (5x10^6) carrying lentivirus RSK4-shRNA while the negative control group of nude mice were subcutaneously injected with MCF-7 cells (5x10^6) carrying lentivirus negative-shRNA, and the blank control group of nude mice were subcutaneously injected with MCF-7 cells (5x10^6). After 35 days, the mice were sacrificed, and the tumors and lungs were harvested. Tumor volume was calculated as: Volume (mm^3) = width^2 (mm^2) x length (mm)/2. Consecutive sections were made of every tissue block of the lungs and subjected to H&E histostaining. The incidence of lung metastasis was evaluated independently by two pathologists. The tumors were collected for quantitative real-time PCR. These experiments were repeated three times to confirm the results.

Statistical analysis. All statistical analysis was performed by using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance (ANOVA), followed by the LSD post hoc test was used to investigate differences between the three groups. Values are expressed as mean ± standard deviation (SD), and a p-value <0.05 was considered statistically significant.

Results

Transfection efficiency. MCF-7 cells transfected with Lentivirus-RSK4-shRNA targeting human RSK4 gene or a non-targeting negative control shRNA exhibiting green fluorescence under a fluorescence microscope were considered to be successfully transfected. Under the lentiviral vector MOI=10 conditions, the expression of GFP stability increased after 72 h, and the lentiviral infection rate was high (Fig. 1A).

Effects of lentivirus-mediated RSK4 RNAi on RSK4 mRNA expression by real-time PCR. In the lentivirus RSK4-shRNA, negative control, and blank control groups, the relative expression levels of RSK4 mRNA were ~0.22±0.06, 0.86±0.05 and 1.00±0.00, respectively. Furthermore, the relative expression levels of RSK4 mRNA in the lentivirus RSK4-shRNA group was significantly lower than levels in the negative (P<0.05) and blank control groups (P<0.05), although there was no statistical significance between negative and blank control groups (P=0.35, Fig. 1C).

Effects of lentivirus-mediated RSK4 RNAi on RSK4 expression by western blot assays. In the lentivirus RSK4-shRNA, negative control, and blank control groups, the relative expression levels of RSK4 protein were ~0.16±0.03, 0.57±0.05 and 0.49±0.04, respectively. The results showed that levels of RSK4 protein in the RSK4-shRNA group was significantly lower than the blank levels (P<0.05) and negative (P<0.05)
control groups, although there was no statistical significance between negative and blank control groups (P=0.62, Fig. 1B).

**Effect of RSK4 knockdown on the proliferation ability of MCF-7 cells.** The MTT assay showed that cell proliferation was significantly promoted in the RSK4-shRNA group as compared to that in the negative and blank control group (P<0.05, Fig. 2A).

**Effects of RSK4 knockdown on the cell cycle of MCF-7 cells.** The number of cells in the G0/G1 phase in the RSK4-shRNA group (63.6±2.8%) was significantly less (P<0.05) than that of the negative (71.3±2.7%) and blank control groups (72.6±3.0%), while the number of cells in S phases in the RSK4-shRNA group (27.4±1.8%) was significantly more (P<0.05) than that of the negative (21.0±1.7%) and blank control groups (19.5±2.5%). However, no significant difference (P>0.05) in the number of cells in the G2/M phase was found in the RSK4-shRNA group (8.9±1.9%), negative (7.6±1.6%) and blank control groups (7.8±1.7%) (Fig. 2B1 and B2).

**Effects of RSK4 knockdown on the invasiveness of MCF-7 cells.** Transwell cell migration assays showed the capacity of MCF-7 cell enhancement, the number of cells in the RSK4-shRNA group migrated through the Matrigel barriers was more than that of the negative (76.8±5.7 vs. 36.1±3.4, P<0.05) and blank control groups (76.8±5.7 vs. 32.5±2.0, P<0.05). No significant difference was observed between the negative group and blank control groups (36.1±3.4 vs. 32.5±2.0, P>0.05) (Fig. 2C).

**In vivo studies of breast adenocarcinoma xenograft tumor model in nude mice.** After 35 days, the tumor tissues were harvested and weighed. The xenografts of the RSK4-shRNA group (933.49±227.51 mm³) had a substantially greater tumors as compared to negative (445.43±126.45 mm³, P<0.05) or blank groups (513.68±141.37 mm³, P<0.05) (Fig. 3A-C). The mean tumor weight derived from the RSK4-shRNA group (1.49±0.25 g) was significantly higher compared to the weights of tumors from the negative (0.77±0.22 g, P<0.05) and blank control groups (0.74±0.18 g, P<0.05) (Fig. 3D). The number of lung metastatic lesions in the RSK4-shRNA group was greatly increased compared with the respective negative (P<0.05) and blank control groups (P<0.05, Fig. 3E and F).

**Effects of lentivirus-mediated RSK4 RNAi on RSK4 mRNA, Ki-67 mRNA, cyclin D1 mRNA, CXC4 mRNA and E-cadherin expression.**
mRNA expression of tumor xenografts by real-time PCR. In the RSK4-shRNA, negative control, and blank control groups, the relative expression levels of RSK4 mRNA were ~0.32±0.10, 0.88±0.08 and 1.000±0.00, the E-cadherin mRNA were ~0.42±0.11, 0.82±0.06 and 1.000±0.00, the CXCR4 mRNA were ~1.48±0.15, 0.82±0.08 and 1.000±0.00, the Ki-67 mRNA were ~1.44±0.07, 0.87±0.07, and 1.000±0.00, the cyclin D1 mRNA were ~1.52±0.09, 0.84±0.08 and 1.000±0.00, respectively. The relative expression levels of RSK4 mRNA and E-cadherin mRNA in the lentivirus RSK4-shRNA group was significantly lower than the levels in the negative (both P<0.05) and blank (both P<0.05) control groups, while the levels of CXCR4 mRNA, Ki-67 mRNA, cyclin D1 mRNA in the lentivirus RSK4-shRNA group were significantly higher than levels that in the blank (both P<0.05) and negative (both P<0.05) control groups (Fig. 4).
RSK4-dependent growth arrest induced by p21cip1 phosphorylation of cells (17). Berns et al showed that RSK4 allowed the cell growth (12). It has been reported that the mouse RSK4 showed high expression, suggesting that RSK4 can inhibit cell proliferation. Thakur et al (19) revealed higher expression of RSK4 was found in normal mammary ductals, and low expression or no expression of RSK4 in benign breast lesions (papilloma). RSK4 is likely to have a role in the development or progression of human breast cancer. This is supported by the finding from Thakur et al study (13). In their study, the overexpressing exogenous RKS4 gene was transfected into the invasive breast cancer cell line MDA-MB-231, and compared with its parental cells, the high expression of RSK4 in transfected MDA-MB-231 showed significantly decreased capacity of cell proliferation, migration, invasion, tumorigenesis and metastasis. It suggested that RSK4 may be a tumor suppressor gene in breast cancer, inhibiting cell proliferation, tumorigenesis and metastasis of breast cancer cells, and that downregulation of RSK4 may promote tumorigenesis and metastasis of breast cancer cells.

Discussion

Breast cancer is one of the most common cancers and the leading cause of cancer death among females worldwide, and invasion and metastasis is an important prognostic factor in patients with breast cancer, and as a serious threat to women’s health. Therefore, further clarifying the mechanism of the development of breast cancer and exploring new therapeutic targets are essential.

Several types of cells were cultured under serum conditions, RSK4 expression was low, but in serum-starved medium, the RSK4 showed high expression, suggesting that RSK4 can restrict cell growth (12). It has been reported that the mouse RSK4 have the ability to inhibit the transcriptional activation of receptor tyrosine kinase (RTK) signaling and extracellular signal-regulated kinase (ERK) signaling on the proliferation of cells (17). Berns et al showed that RSK4 allowed the p53-dependent growth arrest induced by p21 phosphorylation, thus, the knockdown of RSK4 prevented p53-dependent proliferation arrest (18). The above results suggest that RSK4 can inhibit cell proliferation. Thakur et al (19) revealed higher expression of RSK4 was found in normal mammary ductals, and low expression or no expression of RSK4 in benign breast lesions (papilloma). RSK4 is likely to have a role in the development or progression of human breast cancer. This is supported by the finding from Thakur et al study (13). In their study, the overexpressing exogenous RKS4 gene was transfected into the invasive breast cancer cell line MDA-MB-231, and compared with its parental cells, the high expression of RSK4 in transfected MDA-MB-231 showed significantly decreased capacity of cell proliferation, migration, invasion, tumorigenesis and metastasis. It suggested that RSK4 may be a tumor suppressor gene in breast cancer, inhibiting cell proliferation, tumorigenesis and metastasis of breast cancer cells, and that downregulation of RSK4 may promote tumorigenesis and metastasis of breast cancer cells.

RNAi is a highly conserved gene silencing mechanism that introduce double-stranded RNA (dsRNA) to trigger the elimination of the target gene (20). RNAi has been widely used as a powerful tool for gene function analysis and ablating specific genes for therapeutic purpose (21). It has been reported that lentivirus-vector-mediated expression of RNAi display effective and stable gene silencing (22). Compared with other methods, lentiviral vectors may be feasible.

We proposed a hypothesis that downregulation of RSK4 expression in the MCF-7 cell line would affect breast adenocarcinoma tumorigenesis and metastasis. In order to prove this hypothesis, we used lentivirus-mediated siRNA silencing to knock down RSK4 expression in the breast cancer cell line MCF-7, investigated the effect of the RSK4 gene on the cell proliferation and invasion in vitro, and established a model of xenografts in vivo. In the present study, for the first time we investigated the association between RSK4 expression and human breast adenocarcinoma cell proliferation, migration and metastasis status.

We found that knockdown of RSK4 gene promoted the proliferation and invasion of MCF-7 cells in vitro, and the tumor growth was aggressive in RSK4 shRNA transfected tumors while the growth of negative shRNA-infected xenografts and blank control graft slowed down in the mouse model. Furthermore, knockdown of RSK4 dramatically promoted tumorigenicity and increased the number of lung metastatic lesions. It indicate that RSK4 is implicated in the proliferation, invasion and metastasis of MCF-7 cells, and may be manipulated therapeutically to delay the migration and metastasis of MCF-7 cells. We also found that E-cadherin mRNA were downregulated, whereas Ki-67 mRNA, cyclin D1 mRNA, CXCR4 mRNA and E-cadherin mRNA levels were increased in the xenograft tumor in nude mice when RSK4 was knocked down. Several studies have showed that cyclin D1 (23-26), Ki-67 (27,28), E-cadherin (29,30), and CXCR4 (31) play important roles in the development of breast carcinoma. It indicated that lentivirus-mediated RNAi knockdown of RSK4 promoted tumor cell proliferation and migration, and the molecular mechanism may associate with changes of Ki-67, E-cadherin, CXCR4 and cyclin D1.

In conclusion, the present study indicated that RSK4 was a significant tumor suppressor gene contributing to breast tumor development. Furthermore, blocking the RSK4 caused genetic instability, and may lead to upregulation of CXCR4, Ki-67, cyclin D1 gene, and downregulation of E-cadherin gene promoting the proliferation and migration of breast cancer cells.

Acknowledgements

This study was supported by a grant from the National Natural Science Foundation of China (no. 30960427).

References